Abstract: Provided herein are methods of administering a once-nightly dosage of gamma-hydroxybutyrate after a high-fat meal.

Abstract: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.

Abstract: A MEMS microphone assembly has an enclosure enclosing a volume of air. A MEMS microphone chip is provided within the enclosure. First and second acoustic ports are formed in the enclosure, defining first and second fluid paths between the volume of air and air outside the enclosure. The MEMS microphone responds to a pre-determined linear interpolative value between two independent pressure signals supplied via first and second ports according to the potentiometic ratio of the acoustic impedances of the first and second ports.

Abstract: Disclosed are formulations and tablets made therefrom comprising the compound of Formula IA or Formula IB which have sustained-release properties, and the dispersion containing the compounds of Formula IA or IB which facilitates such sustained release: Formula IA, Formula IB.

Abstract: A MEMS microphone assembly has an enclosure enclosing a volume of air. A MEMS microphone chip is provided within the enclosure. First and second acoustic ports are formed in the enclosure, defining first and second fluid paths between the volume of air and air outside the enclosure. The MEMS microphone responds to a pre-determined linear interpolative value between two independent pressure signals supplied via first and second ports according to the potentiometic ratio of the acoustic impedances of the first and second ports.

Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified ?-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.

Abstract: Pharmaceutical compositions for intravenous administration comprising the compound of Formula I or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein.

Abstract: The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s).

Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified ?-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.

Abstract: Pharmaceutical compositions for intravenous administration comprising the compound of Formula I or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein.

Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified ?-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.

Abstract: The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s).

Abstract: The invention provides earphone arrangements for use with electronic host devices, such as cellular telephone handsets and music storage and reproduction devices, and it provides in particular earphone arrangements with ambient noise cancellation (“ANC”). Typically, in prior arrangements, the complex signal processing required for ANC is carried out in the earphones themselves and/or in a pod connected between the earphones and the host device. The invention configures the processing elements such that the ANC signal-processing function is transferred to an ANC processor incorporated into the host device.

Abstract: The present invention relates to aqueous solutions useful as pharmaceutical compositions of posaconazole for intravenous administration. These compositions include a solubilizing agent, such as a modified ?-cyclodextrin in an acidified solution, which can also include a chelating agent such as disodium edetate (EDTA). In clinical trials, a 200 mg posaconazole dose of the selected composition was found to achieve acceptable pharmacokinetic properties.

Abstract: This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and can be used for the treatment of diseases of the upper and/or lower airway passages.

Abstract: The present invention is directed toward an apparatus for efficient, durable, reliable, and cost-effective fluid injection. In particular, the present invention provides an unpowered device for automatic fluid injection dictated by pressure differential in the line. More specifically, the present invention provides a device for injecting a degreasing chemical into air relief valves in municipal wastewater systems, which operates off of the differential pressure in the pumped lines resulting from the pump operating cycles.

Abstract: A method and apparatus for testing the functionality of automatic air valves positioned at high points of a pipeline system are provided. The invention generally provides a testing flange and a process for performing various fluid pressure tests to determine whether automatic air valves are properly releasing and/or stabilizing air within a pipeline system.

Abstract: The present invention is directed toward an apparatus for efficient, durable, reliable, and cost-effective fluid injection. In particular, the present invention provides an unpowered device for automatic fluid injection dictated by pressure differential in the line. More specifically, the present invention provides a device for injecting a degreasing chemical into air relief valves in municipal wastewater systems, which operates off of the differential pressure in the pumped lines resulting from the pump operating cycles.

Abstract: Pharmaceutical compositions for intravenous administration comprising the compound of Formula I or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein.

Abstract: The present invention provides formulations of therapeutic agents that benefit from a prolonged time of controlled release in the stomach and upper gastrointestinal (GI) tract, and from an enhanced drug exposure to the upper GI tract. The formulations of the invention comprise a therapeutic agent and one or more pH sensitive polymers that are designed for accelerated hydration, expansion, disintegration and dissolution at the higher pH of the upper GI tract, thereby, ensuring that any therapeutic agent that has not been released in the stomach is released in the upper GI tract, thus maximizing absorption of therapeutic agent that has a window of absorption located at the upper GI tract.